Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool
ViiV announced new collaborations to increase access to its HIV medicine, dolutegravir ( Tivicay®), just after approval by EMA & FDA.
-
GSK announces new strategic investments in Africa to increase access to medicines, build capacity and deliver sustainable growth
GSK today announced a series of investments in sub-Saharan Africa designed to address pressing needs and contribute to long-term growth.
-
Regulatory update: Votrient® (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU
GSK today announced that it has withdrawn application to EMA for a variation to the Marketing Authorisation for Votrient® (pazopanib).
-
GSK presents data from Phase III STABILITY study of darapladib in patients with chronic coronary heart disease
GSK presented data from the pivotal Phase III STABILITY study of darapladib at the American College of Cardiology 63rd Annual Session
-
GSK acquires full ownership of its Indonesian Consumer Healthcare business
GSK has acquired full ownership of its Indonesian Consumer Healthcare business
-
Where do you start when developing a new medicine?
Initiative between GSK, EMBL-EBI and Sanger Institute is using ‘big data’ & genome sequencing improving chances for discovering new drugs.
-
GSK receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan® (albiglutide)
GSK announced that the EC has granted marketing authorisation for its once-weekly diabetes treatment, Eperzan® (albiglutide).
-
Regulatory update: combined use of Mekinist™ (trametinib) and Tafinlar® (dabrafenib) in Europe
GSK today announced that it has withdrawn its MAA to EMA for the use of Mekinist (trametinib) in combination with Tafinlar (dabrafenib).
-
GSK publishes historical quarterly restated financial information
GSK will adopt a revised presentation for the analysis of its Pharmaceuticals and Vaccines turnover by segment, product and therapeutic area
-
Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial
GSK announced that the MAGRITi phase III trial of MAGE-A3 cancer immunotherapeuticii in NSCLC patients did not meet its primary endpoint.
-
GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS® in patients with COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from three phase III studies.
-
Patient recruitment completes in landmark RELVAR®/ BREO® ELLIPTA® Study to Understand Mortality and MorbidITy (SUMMIT) in COPD
GSK & THRX announced that recruitment of patients into the study known as SUMMIT, has completed enrolment.
-
GSK announces positive results from phase III studies for mepolizumab in severe eosinophilic asthma
GSK announced that, pivotal phase III study of mepolizumab, an investigational IL-5 antagonist monoclonal antibody, met its primary endpoint
-
GSK increases stake in Indian Pharmaceuticals subsidiary to 75 per cent after Open Offer
GSK announced that, it has successfully increased its stake in its publicly-listed pharmaceuticals subsidiary in India.
-
GSK announces submission to U.S. regulatory authorities for Promacta™ (eltrombopag) for severe aplastic anaemia
GSK announced the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA for Promacta™ (eltrombopag).
-
GSK kicks off 2014 Discovery Fast Track Challenge for academic drug hunters in Europe, Canada and USA
GSK is inviting academic scientists to enter their most innovative drug research proposals into its 2014 Discovery Fast Track Challenge.
-
Anoro® (umeclidinium / vilanterol) receives positive opinion from the CHMP in Europe for the treatment of COPD
GSK & THRX announced that CHMP of EMA has issued a positive opinion recommending marketing authorisation for UMEC/VI ,brand name Anoro®
-
GSK receives positive CHMP opinion for Incruse® (umeclidinium) for the treatment of COPD
GSK announced that EMA's CHMP is recommending marketing authorisation for umeclidinium, treatment to relieve symptoms in patients with COPD.
-
GSK announces start of Phase lll study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis
GSK today announced the start of a Phase III study to evaluate the efficacy and safety of mepolizumab, an investigational IL-5 antagonist.
-
Results announcement for fourth quarter 2013
GSK announces core EPS of 112.2p and dividend of 78p.
